At present, our research drug for the indications of idiopathic pulmonary fibrosis (IPF) is a TGF-β peptide inhibitor, and there is no similar competitive product in the world. The drug has completed the pre-clinical research and has submitted a Class 1 new drug clinical trial application to the China National Medical Products Administration, and intends to submit an application to the U.S. Food and Drug Administration.


As the company’s IPF project moves into the clinical trials, we will horizontally expand the R&D programs of candidate peptide into clincal trials for multiple indications, based on the compatibility of mechanisms (involving vital organs such as liver, kidney fibrosis and solid tumors). New dosage forms of the project are also being  researched and developed in cooperation with experienced pharmaceutical companies in China.